Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) was inhibitory to four strains of avian H5N1 influenza virus in MDCK cells, with the 90% effective concentrations ranging from 1.3 to 7.7 microM, as determined by a virus yield reduction assay. The efficacy was less than that exerted by oseltamivir carboxylate or zanamivir but was greater than that exerted by ribavirin. Experiments with mice lethally infected with influenza A/Duck/MN/1525/81 (H5N1) virus showed that T-705 administered per os once, twice, or four times daily for 5 days beginning 1 h after virus exposure was highly inhibitory to the infection. Dosages from 30 to 300 mg/kg of body weight/day were well tolerated; each prevented death, lessened the decline of arterial oxygen saturation (SaO(2)), and inhibited lung consolidation and lung virus titers. Dosages from 30 to 300 mg/kg/day administered once or twice daily also significantly prevented the death of the mice. Oseltamivir (20 mg/kg/day), administered per os twice daily for 5 days, was tested in parallel in two experiments; it was only weakly effective against the infection. The four-times-daily T-705 treatments at 300 mg/kg/day could be delayed until 96 h after virus exposure and still significantly inhibit the infection. Single T-705 treatments administered up to 60 h after virus exposure also prevented death and the decline of SaO(2). Characterization of the pathogenesis of the duck influenza H5N1 virus used in these studies was undertaken; although the virus was highly pathogenic to mice, it was less neurotropic than has been described for clinical isolates of the H5N1 virus. These data indicate that T-705 may be useful for the treatment of avian influenza virus infections.
Sidwell
Robert W
RW
Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA. Rsidwell@cc.usu.edu
Barnard
Dale L
DL
Day
Craig W
CW
Smee
Donald F
DF
Bailey
Kevin W
KW
Wong
Min-Hui
MH
Morrey
John D
JD
Furuta
Yousuke
Y
D000577:Amides / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002478:Cells, Cultured; D003588:Cytopathogenic Effect, Viral; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008168:Lung / Q000473:pathology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D053139:Oseltamivir / Q000627:therapeutic use; D010100:Oxygen / Q000097:blood; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D016019:Survival Analysis; D014779:Virus Replication / Q000187:drug effects
D000577:Amides; D000998:Antiviral Agents; D011719:Pyrazines; D053139:Oseltamivir; C462182:favipiravir; D010100:Oxygen